<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="180">
  <stage>Registered</stage>
  <submitdate>11/08/2005</submitdate>
  <approvaldate>16/08/2005</approvaldate>
  <actrnumber>ACTRN12605000159651</actrnumber>
  <trial_identification>
    <studytitle>The effect of weight loss on Type 2 Diabetes: a prospective randomized controlled trial of best practice medical management versus the placement of the Lap-Band System on HbA1c concentration.</studytitle>
    <scientifictitle>The effect of weight loss on Type 2 Diabetes: a prospective randomized controlled trial of best practice medical management versus the placement of the Lap-Band System on HbA1c concentration.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Type 2 Diabetes</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Sixty patients who have been diagnosed as having Type 2 diabetes within the last two years will be randomly allocated to having Lap-Band placement and community best practice diabetic care or to community best practice diabetic care alone. Patient follow up will continue for 2 years from randomization.</interventions>
    <comparator>Community best practice diabetic care alone.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: surgery</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The biochemical assessment of glycaemic control of Type 2 diabetes using HbA1c concentration</outcome>
      <timepoint>At 2 years from randomisation</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Biochemical assessment of fasting plasma lipids</outcome>
      <timepoint>At 12 and 24 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assessment of blood pressure</outcome>
      <timepoint>At 12 and 24 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Medication used to treat hyperglycaemia and hypertension</outcome>
      <timepoint>At 12 and 24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Morbidity and mortality associated with diabetes, obesity or treatment of these conditions</outcome>
      <timepoint>At 24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome> The achievement and sustainability of weight loss. </outcome>
      <timepoint>At 24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Additional biochemical endpoints will include indirect measures of insulin resistance and beta cell function using the homeostatic model assessment using fasting plasma glucose and C-peptide concentrations, liver function tests, and an assessment of renal function and presence of microalbuminuria. T</outcome>
      <timepoint>At 12 and 24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The costs of all diabetes and obesity related treatments including surgery and medications would be assessed. </outcome>
      <timepoint>At 24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Other clinical comorbidities including obstructive sleep apnoea and ovulatory dysfunction would also be assessed.</outcome>
      <timepoint>At 24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life and functional status will be assessed using the SF36, Multi-Dimensional Body-Self Relations questionnaire and the Beck Depression Inventory, and employment details. </outcome>
      <timepoint>At 12 and 24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The costs of managing diabetes and obesity in both groups will be recorded and the side effects and/or complications of any treatment of diabetes or obesity will be noted.</outcome>
      <timepoint>At 24 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients will have a BMI greater than 30 and less than 40kg/m2, have been diagnosed with Type 2 diabetes within the last two years, have no evidence of renal impairment, microalbuminuria or retinopathy, be able to understand the options and study requirements and to comply with the either arm of the study, and be willing to be randomized. </inclusivecriteria>
    <inclusiveminage>30</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Unwillingness to accept the randomization process, history of previous abdominal surgery which would potentially preclude laparascopic placement of the band, a history of previous obesity surgery, any contraindication to Lap-Band placement, medical issues which contraindicated the application of either arm of the study (these would include; acute myocardial infarction within the past 6 months, dementia, active psychosis, concurrent experimental drug use, autoimmune disease, pregnancy, lactation, illicit drug use, excessive alcohol intake, use of drugs known to affect body composition, cytotoxic drugs, internal malignancy or major organ failure) , systemic lupus erythematosis or other auto-immune disease, direct hypothalamic damage as a cause of obesity, inability to understand the risks, realistic benefits and compliance requirements of the Lap-Band intervention and conventional management of diabetes, Type 1 diabetes or diabetes secondary to specific diseases foe example haemochromatosis or chronic pancreatitis.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Intervention recorded and stored in numbered, sealed opaque envelopes organized and maintained by staff member not involved in patient care or scheduling and opened in sequence as randomized.</concealment>
    <sequence>Subjects were block randomized in groups with equal numbers in both treatment arms. The sequence within blocks was determined by drawing allocation out of a hat.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/02/2003</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Centre for Obesity Research and Education (CORE)</primarysponsorname>
    <primarysponsoraddress>Commercial Road 
Melbourne Vic 3004</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Centre for Obesity Research and Education (CORE) Monash University</fundingname>
      <fundingaddress>Commercial Road
Melbourne Vic 3004</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Inamed Health</fundingname>
      <fundingaddress>5540 Ekwill Street
Santa Barbara CA 93111</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>none</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication>Presentation: American Diabetes Association meeting, Chicago, June 2007. Abstract Number 1834-P-"Randomised Trial of Surgically-induced Weight Loss for Obeses subjects with Type-2 Diabetes".
Publication: Dixon JB, O'Brien PE, Playfair J, Chapman L, Schachter LM, Skinner S, Proietto J, Bailey M, Anderson M: Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. Jama 299:316-323, 2008</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Avenue Hospital, Melbourne</ethicname>
      <ethicaddress>The Avenue
Windsor Vic 3181</ethicaddress>
      <ethicapprovaldate>7/08/2002</ethicapprovaldate>
      <hrec>Trial 033</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Monash University SCERH</ethicname>
      <ethicaddress>Building 3D, Clayton Campus
Wellington Road
Clayton Vic</ethicaddress>
      <ethicapprovaldate>4/09/2003</ethicapprovaldate>
      <hrec>2003/459MC</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Associate  Professor John Dixon</name>
      <address>School of Primary Health Care
Building 1, 270 Ferntree Gully Road
Notting Hill Vic 3168</address>
      <phone>+61 3 9501 2431</phone>
      <fax>+61 3 8575 2233</fax>
      <email>john.dixon@med.monash.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ms Julie Playfair</name>
      <address>Centre for Obesity Research and Education (CORE)
Monash University Medical School
Alfred Hospital
Commercial Road
Melbourne VIC 3004</address>
      <phone>+61 3 99030721</phone>
      <fax>+61 3 95103365</fax>
      <email>julie.playfair@med.monash.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Mrs Maureen Dixon</name>
      <address>School of Primary Health Care
Building 1, 270 Ferntree Gully Road
Notting Hill 3168</address>
      <phone>+61 3 8575 2273</phone>
      <fax>+61 3 8575 2233</fax>
      <email>maureen.dixon@med.monash.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>